IKNA Ikena Oncology Inc
Price (delayed)
$1.25
Market cap
$60.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
$28.45M
Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that
Highlights
IKNA's EPS is up by 37% year-on-year and by 16% since the previous quarter
The debt has contracted by 30% YoY and by 10% from the previous quarter
IKNA's gross profit has shrunk by 100% QoQ and by 100% YoY
Ikena Oncology's revenue has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of IKNA
Market
Valuations
Earnings
Shares outstanding
48.26M
Market cap
$60.32M
Enterprise value
$28.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$58.97M
Net income
-$49.23M
EBIT
-$49.08M
EBITDA
-$46.54M
Free cash flow
-$45.57M
Per share
Balance sheet
Liquidity
EPS
-$1.02
EPS diluted
-$1.02
Free cash flow per share
-$0.94
Book value per share
$2.61
Revenue per share
$0
TBVPS
$2.93
Total assets
$141.51M
Total liabilities
$15.58M
Debt
$7.52M
Equity
$125.93M
Working capital
$116.39M
Debt to equity
0.06
Current ratio
11.8
Quick ratio
11.54
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-31.7%
Return on equity
-35.3%
Return on invested capital
-45.1%
Return on capital employed
-37.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IKNA stock price
How has the Ikena Oncology stock price performed over time
Intraday
0%
1 week
-3.85%
1 month
-6.72%
1 year
-6.72%
YTD
-23.78%
QTD
-2.34%
Financial performance
How have Ikena Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$58.97M
Net income
-$49.23M
Gross margin
N/A
Net margin
N/A
IKNA's gross profit has shrunk by 100% QoQ and by 100% YoY
Ikena Oncology's revenue has shrunk by 100% QoQ and by 100% YoY
The company's net income rose by 28% YoY and by 17% QoQ
The operating income rose by 22% YoY and by 14% QoQ
Growth
What is Ikena Oncology's growth rate over time
Valuation
What is Ikena Oncology stock price valuation
P/E
N/A
P/B
0.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
IKNA's EPS is up by 37% year-on-year and by 16% since the previous quarter
The stock's price to book (P/B) is 63% less than its 5-year quarterly average of 1.3 and 20% less than its last 4 quarters average of 0.6
IKNA's equity is down by 26% year-on-year and by 6% since the previous quarter
Ikena Oncology's revenue has shrunk by 100% QoQ and by 100% YoY
Efficiency
How efficient is Ikena Oncology business performance
Ikena Oncology's ROIC has increased by 40% YoY and by 23% from the previous quarter
Ikena Oncology's ROE has increased by 20% YoY and by 11% from the previous quarter
IKNA's return on assets is up by 15% year-on-year and by 11% since the previous quarter
Dividends
What is IKNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IKNA.
Financial health
How did Ikena Oncology financials performed over time
Ikena Oncology's total liabilities has decreased by 30% YoY but it has increased by 6% from the previous quarter
The total assets has contracted by 26% YoY and by 5% from the previous quarter
The debt is 94% less than the equity
The debt has contracted by 30% YoY and by 10% from the previous quarter
IKNA's equity is down by 26% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.